Quality of life in intensively treated youths with early-onset type 1 diabetes: a population-based survey

Stahl‐Pehe, Anna; Straßburger, Klaus; Castillo, Katty; Bächle, Christina; Holl, Reinhard W.; Lange, Karin; Rosenbauer, Joachim

doi:10.1111/pedi.12096

Cited by 41 publications

(57 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetes‐specific measures are designed to cover meaningful aspects of the disease and its treatment, and hence, offer a greater depth of insight to the experiences of patients. They are also more sensitive to treatment differences …”

Section: Introductionmentioning

confidence: 99%

Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial

et al. 2018

View full text Add to dashboard Cite

Objective Continuous subcutaneous insulin infusion (CSII) is on the rise among pediatric patients with type 1 diabetes mellitus. Metabolic effects alone cannot explain this rising popularity. From the patient's perspective, the main benefits of CSII may be found in subjective psychosocial health outcomes (patient‐reported outcomes [PRO]). Subjects and Methods In a multicenter open randomized controlled trial, children and adolescents aged 6 to16 years currently treated with multiple daily injections (MDI) were randomized 1:1, stratified by center, to either starting with CSII immediately after the baseline interview or to continuing MDI while waiting 6 months for transmission to CSII. The primary outcomes were patient‐reported diabetes‐specific health‐related quality of life (DHRQOL) and diabetes burden of the main caregiver. Secondary outcomes were caregiver stress, fear of hypoglycemia, satisfaction with treatment, and HbA1c. Results Two‐hundred and eleven patients were randomized between February 2011 and October 2014, and 186 caregivers and 170 patients were analyzed using the intention‐to‐treat principle for primary outcomes. Children 8 to 11 years in the CSII group reported improved DHRQOL at follow‐up compared to MDI (median difference [MD] 9.5, 95% confidence interval [CI] 3.6‐16.7, P = 0.004). There were no treatment differences in the adolescent age‐group 12 to 16 years (MD 2.7; 95% CI −3.2‐9.5; P = 0.353). The main caregivers of the CSII group reported a significant decline of overall diabetes burden at follow‐up compared to the MDI group (MD 0; 95% CI −1‐0; P = 0.029). Secondary PROs also were in favor of CSII. Conclusions CSII has substantial psychosocial benefits. PROs demonstrate these benefits. Registered as NCT01338922 at http://clinicaltrials.gov

show abstract

Section: Introductionmentioning

confidence: 99%

Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The study design of the baseline‐survey conducted 2009 to 2010 has been described in detail previously . In summary, the 840 participants of this questionnaire survey had an onset of disease during the period of 1993‐1999 when the patients were younger than 5 years old.…”

Section: Methodsmentioning

confidence: 99%

“…A multitude of cross‐sectional studies with diabetic youths have already shown that glycemic control and QoL are related to each other. A common finding is that better QoL is observed in patients with lower hemoglobin A1c (HbA1c) . To date, it is not conclusively established whether poor glycemic control results in impaired QoL or vice versa.…”

Section: Introductionmentioning

confidence: 99%

Impact of quality of life (QoL) on glycemic control (HbA1c) among adolescents and emerging adults with long-duration type 1 diabetes: A prospective cohort-study

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…[15][16][17] The Kindl ® questionnaire consists of 30 questions grouped under their domains related to physical and emotional well-being, self-esteem, family, friends, school and disease, resulting in a global score of 0-100. It was previously used in several studies, especially for children with chronic diseases.…”

Section: Interventionsmentioning

confidence: 99%

Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission—A cross‐sectional study

et al. 2019

View full text Add to dashboard Cite

Aim: Severe forms of idiopathic nephrotic syndrome (INS) require immunosuppressive therapy: oral treatment or intravenous therapy (rituximab, RTX). The main objective was to describe quality of life (QOL) in these specific patients.Methods: Cross-sectional, multicentre, observational study analysed QOL using a standardised questionnaire in children from 7 to 17 years, with a steroid-dependent or steroid-resistant INS in stable remission. The questionnaire consisted of 30 questions concerning physical and emotional well-being, self-esteem, family, friends, school and disease resulting in a global score of 0-100. Results: A total of 110 patients with a mean age of 11.6 years from three French paediatric nephrology centres were included. A total of 71 patients had oral immunosuppressive treatment, 27 had RTX, and 12 had both. 13.6% of patients had a steroid-resistant INS. The mean number of relapses was 5.8. Seventy-eight patients answered the questionnaire. The global score in the whole study population was 74.7; 72.6 in the RTX group, 76.2 in the oral drugs group, (P = 0.49). The results of sub-dimension 'school' were statistically lower in RTX group (61.6 ± 19.5) compared with oral drugs group (71.4 ± 16; P = 0.02). Conclusion: Global QOL score was high in 'difficult-to-treat' patients with INS in stable remission on oral immunosuppressive or RTX treatment. K E Y W O R D S children and adolescents, immunosuppression, nephrotic syndrome, quality of life 2268 | ROUSSEL Et aL. S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section at the end of the article. How to cite this article: Roussel A, Delbet J-D, Micheland L, Deschênes G, Decramer S, Ulinski T. Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission-A cross-sectional study. Acta Paediatr.

show abstract

Quality of life in intensively treated youths with early-onset type 1 diabetes: a population-based survey

Abstract: Good glycemic control and a high level of treatment satisfaction are associated with a positive QoL in youths with early-onset type 1 diabetes.

Cited by 41 publications

References 33 publications

Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial

Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial

Impact of quality of life (QoL) on glycemic control (HbA1c) among adolescents and emerging adults with long-duration type 1 diabetes: A prospective cohort-study

Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission—A cross‐sectional study

Contact Info

Product

Resources

About